A new global analysis published in The Lancet Gastroenterology & Hepatology reports that cases of metabolic dysfunction-associated steatotic liver disease (MASLD) have surged 143% since 1990, reaching an estimated 1.3 billion people in 2023, according to the study, as reported by registered dietitian Molly Knudsen. The condition, driven by metabolic risk factors including high fasting plasma glucose, high body mass index (BMI), and smoking, is projected to affect 1.8 billion people by 2050 unless interventions are implemented, researchers stated. Liver cancer cases are expected to nearly double from 870,000 in 2022 to 1.52 million by 2050, with MASLD identified as...